Item 2.02.Results of Operations and Financial Condition.

On July 29, 2021, CRISPR Therapeutics AG announced its financial results for the quarter ended June 30, 2021 and other business highlights. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01.Financial Statements and Exhibits.

(d) Exhibits:

The following exhibits shall be deemed to be furnished, and not filed:





Exhibit
  No.     Description

99.1        Press Release by CRISPR Therapeutics AG, dated July 29, 2021

104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses